Javier Munoz is an Oncology physician affiliated with Mayo Clinic Hospital. OpenAlex indexes 284 publications with 20,309 citations (h-index 46); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5881 E Mayo Blvd
Phoenix, AZ 850544504
Telephone
480-342-4800Provider last certified this registry record 9 Sept 2020.
Clinical trials
- Comparision of Hydrodilatation Results at Different Volumes in Adhesive Capsulitis by Phases.
Sponsor: Javier Muñoz Paz
- Calciying Tendinopathy of the Rotator Cuff: Barbotage Vs Shock Waves
Sponsor: Maimónides Biomedical Research Institute of Córdoba
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Celgene CorporationProgram year20251 payment
- Phathom Pharmaceuticals, Inc.Program year20241 payment
- Genmab U.S., Inc.Program year202315 payments$17,128openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
70.6%PD-1 inhibitor25.1%Pembrolizumab71%Nivolumab29%Part B, office-administered≥52 patientsCD38-directed Cytolytic Antibody16.7%Daratumumab100%Part B, office-administered≥58 patients+ 8 more classes in this area
Metabolism & gastrointestinal
14%Other antiemetics11.1%Fosaprepitant100%Part B, office-administered≥49 patientsSerotonin-3 Receptor Antagonist2.2%Palonosetron hcl58%Ondansetron hydrochloride40%Ondansetron Hcl2%Part D + Part B≥82 patients+ 3 more classes in this area
Blood & clotting
8.1%Erythropoiesis-stimulating Agent8.1%Darbepoetin alfa100%Part B, office-administered≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis
Biology of Blood and Marrow Transplantation
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Douglas Faigel, MD
Mayo Clinic Hospital
Shimon Kusne, MD
Mayo Clinic Hospital
Deborah Keller, MD
Mayo Clinic Hospital
Devyani Lal, MD
Mayo Clinic Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”